Vol. 48, No. 4, 2005
Issue release date: July–August 2005
Intervirology 2005;48:268–272
(DOI:10.1159/000084605)
Case Report
Add to my selection

Primary Sclerosing Cholangitis and Hepatitis C Virus Infection

Kim S.R.a · Imoto S.a · Taniguchi M.b · Kim K.I.c · Sasase N.c · Matsuoka T.d · Maekawa Y.a · Ninomiya T.a · Ando K.a · Mita K.a · Fuki S.a · Koterazawa T.a · Fukuda K.a · Kudo M.e · Sakamoto H.e · Hayashi Y.f
aDepartment of Gastroenterology, bMedical Information Center, and cDepartment of Pharmacy, Kobe Asahi Hospital, Kobe; dDepartment of Radiology, Osaka City University Medical School, Osaka; eDepartment of Gastroenterology, Kinki University School of Medicine, Osakasayama, and fDivision of Molecular Medicine and Medical Genetics, International Center for Medical Research and Treatment (ICMRT), Kobe University Graduate School of Medicine, Kobe, Japan
email Corresponding Author


 goto top of outline Key Words

  • Primary sclerosing cholangitis
  • Hepatitis C virus
  • Endoscopic retrograde cholangiopancreatography
  • Human leukocyte antigen
  • Onionskin lesion

 goto top of outline Abstract

Two cases of primary sclerosing cholangitis with hepatic C virus infection in a 62-year-old man and a 60-year-old woman are presented. The infection in the man was eradicated with interferon therapy in 1992. Seven years thereafter, endoscopic retrograde cholangiography revealed a diffuse 2.5-cm-long stenotic lesion in the common bile duct which was consequently resected. Histological examination of the resected specimen revealed proliferation of epithelial cells, plasma cell infiltration, and fibrosis in the submucosal layer of the common bile duct. The human leukocyte antigen DR loci were 2 and 9. In the woman, a 6-month course of interferon therapy in 1992 failed to eradicate the infection. Cholangiography in 1999 revealed multiple narrowings and dilatations of intra- and extrahepatic bile ducts. Ultrasound guided biopsy of the liver in 1992 had revealed onionskin lesions around the bile duct epithelium in the portal tract. The human leukocyte antigen DR locus was 2. From these findings, the 2 cases were diagnosed as primary sclerosing cholangitis. Further studies may provide insights into the relation between the pathogenesis of the disease and the infection.

Copyright © 2005 S. Karger AG, Basel


 goto top of outline References
  1. Chapman RWG, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S: Primary sclerosing cholangitis: A review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21:870–877.
  2. Lefkowitch JH: Primary sclerosing cholangitis. Arch Intern Med 1982;142:1157–1160.
  3. LaRusso NF, Wiesner RH, Ludwing J, MacCarty RL: Primary sclerosing cholangitis. N Engl J Med 1984;310:899–903.
  4. Lindor KD, Wiesner RH, LaRusso NF: Recent advances in the management of primary sclerosing cholangitis. Semin Liver Dis 1987;7:322–327.
  5. Angulo P, DeSotel CK, Gershwin ME, Shoenfeld Y, Ahmed A, Peter J, Lindor KD: The profile and significance of serum autoantibodies in primary sclerosing cholangitis (abstract). Hepatology 1998;28:444A.
  6. Lichtman SN, Sartor RB, Keku J, Schwab JH: Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990;98:414–423.
  7. Vinnik IE, Kern F Jr, Struthers JE Jr, Hill RB, Guzak S: Experimental chronic portal vein bacteremia. Proc Soc Exp Biol Med 1964;115:311–314.
  8. Angulo P, Lindor KD: Primary sclerosing cholangitis. Hepatology 1999;30:325–332.
  9. Finegold MJ, Carpenter RJ: Obliterative cholangitis due to cytomegalovirus. A possible precursor of paucity of intrahepatic bile ducts. Hum Pathol 1982;13:662–665.
  10. Ludwig J, Kim CH, Wiesner RH, Krom RAF: Floxuridine-induced sclerosing cholangitis. An ischemic cholangiopathy? Hepatology 1989;9:215–218.
  11. Carey JB Jr: Bile acids, cirrhosis, and human evolution. Gastroenterology 1964;46:490–493.
  12. Quigley EMM, LaRusso NF, Ludwig J, MacSween RNM, Birnie GG, Watkinson G: Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983;85:1160–1165.
  13. Jorge AD, Esley C, Ahumada J: Family incidence of primary sclerosing cholangitis associated with immunologic diseases. Endoscopy 1987;19:114–117.
  14. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis. A comparative analysis. Hepatology 1992;15:572–577.
  15. Lefkowitch JH, Schiff ER, Davis GL, Perrilo RP, Lindsay K, Bodenheimer HC, Balart LA, Ortego TJ, Payne J, Dienstag JL, and the Hepatitis Interventional Therapy Group: Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104:595–603.
  16. Haruna Y, Kanda T, Honda M, Takao T, Hayashi N: Detection of hepatitis C virus in the bile and bile duct epithelial cells of hepatitis C virus-infected patients. Hepatology 2001;33:977–980.
  17. Bartholomew LG, Gain JC, Woolner LB, Utz DC, Ferris DO: Sclerosing cholangitis. Its possible association with Riedel’s struma and fibrous retroperitonitis. Report of two cases. N Engl J Med 1963;269:8–12.
  18. Alperti LI, Jindrak K: Idiopathic retroperitonal fibrosis and sclerosing cholangitis associated with a reticulum cell sarcoma. Gastroenterology 1972;62:111–117.

    External Resources

  19. Hawk WA, Hazard JB: Sclerosing retroperitonitis and sclerosing mediastinitis. Am J Clin Pathol 1959;32:321–334.
  20. Hellstrom HR, Perez-Stable EC: Retroperitoneal fibrosis with disseminated vasculitis and intrahepatic sclerosing cholangitis. Am J Med 1966;40:184–187.
  21. Thompson HH, Pitt HA, Lewin KJ, Longmire WP: Sclerosing cholangitis and histiocytosis X. Gut 1984;25:526–530.
  22. Concepcion W, Houssein D, Nakazato P, Cox K, Terry A, Esquivel CO: Transplantation for liver failure due to histiocytosis (abstract). Hepatology 1989;10:A658.
  23. Alberti-Flor JJ, Kalemeris G, Dunn GD, Avant GR: Primary sclerosing cholangitis associated with massive intraabdominal lymphadenopathy. Am J Gastroenterol 1986;81:55–60.
  24. Bass NM, Chapman RW, O’Rielly A, Sherlock S: Primary sclerosing cholangitis associated with angioimmunoblastic lymphadenopathy. Gastroenterology 1983;85:420–424.

    External Resources

  25. Montefusco PP, Geiss AC, Bronzo RL, Randall S, Kahn E, McKinley MJ: Sclerosing cholangitis, chronic pancreatitis and Sjögren’s syndrome. A syndrome complex. Am J Surg 1984;147:822–826.
  26. Gupta S, Saverymuttu SH, Marsh JCW, Hodgson HJ, Chadwick VS: Immune thrombocytopenic purpura, neutropenia and sclerosing cholangitis associated with ulcerative cholangitis in an adult. Clin Lab Haematol 1986;8:67–69.
  27. Danzi JT, Makipour H, Farmer RG: Primary sclerosing cholangitis. A report of nine cases and clinical review. Am J Gastroenterol 1976;65:109–116.
  28. Mir-Madjlessi SH, Sivak MV, Farmer RG: Hypereosinophilia, ulcerative colitis, primary sclerosing cholangitis and bile duct carcinoma. Am J Gastroenterol 1986;81:483–485.
  29. Man VM, Drejet A, Keeffe EB, Garcia-Kennedy R, Imperial JC: Primary sclerosing cholangitis and Hodgkin’s disease. Hepatology 1995;18:1127–1131.
  30. Jorge AD, Esley C, Ahumada J: Family incidence of primary sclerosing cholangitis associated with immunologic diseases. Endoscopy 1987;19:114–117.
  31. Chapman RW, Varghese Z, Grul R, Patel G, Kokinon N, Sherlock S: Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38–41.
  32. Schrumft E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E: HLA antigens and immunoregulatory T cell in ulcerative colitis associated with hepatobiliary diseases. Scand J Gastroenterol 1982;17:187–191.
  33. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R: Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13:129–133.
  34. Mehal WZ, Lo YM, Wordsworth BP, Nauberger JM, Hubscher SC, Fleming KA, Chapman RW: HLA DR4 is a marker for rapid diseases progression in primary sclerosing cholangitis. Gasteroenterology 1994;106:160–167.
  35. Eddleston AL, Williams R: HLA and liver diseases. Br Med Bull 1978;34:295–300.
  36. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW: Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990;322:1842–1844.
  37. Sharma AN, Arora S, Rabson AR, Kaplan MM: HLA-DRw52a and primary sclerosing cholangitis (PSC). Linkage but less than 100% (abstract). Hepatology 1991;14:196A.
  38. Anglo P, DeSotel CK, Gershwin ME, Shoenfeld Y, Ahmed A, Peter J, Lindor LD: The profile and significance of serum autoantibodies in primary sclerosing cholangitis (abstract). Hepatology 1998;28:444A.
  39. Boberg KM, Schrumpf E, Fausa O, Elgjo K, Kolmannskog F, Haaland T: Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified as small-duct primary sclerosing cholangitis. Scand J Gastroenterol 1994;29:144–152.
  40. Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Shanahan F: Neutrophil cytoplasmic antibodies. Link between sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;100:1385–1391.
  41. Klein R, Eisenburg J, Weber P, Seibold F, Berg PA: Significance and specificity of antibodies to neutrophils detected by Western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991;14:1447–1452.

    External Resources

  42. Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM: Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993;17:411–417.
  43. Das KM, Vecchi M, Sakamaki S: A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990;98:464–469.
  44. Gumber SC, Chopra S: Hepatitis C: A multifaceted disease. Review of extrahepatic manifestation. Ann Intern Med 1995;123:615–620.
  45. Hirohata S, Inoue T, Ito K: Development of rheumatoid arthritis after chronic hepatitis caused by hepatitis C virus infection. Internal Med 1992;31:493–495.

 goto top of outline Author Contacts

Soo Ryang Kim, MD
Department of Gastroenterology, Kobe Asahi Hospital
3-5-25 Bouoji-cho
Nagata-ku, Kobe 653-0801 (Japan)
Tel. +81 78 612 5151, Fax +81 78 612 5152, E-Mail asahi-hp@arion.ocn.ne.jp


 goto top of outline Article Information

Received: April 23, 2004
Accepted after revision: August 12, 2004
Number of Print Pages : 5
Number of Figures : 4, Number of Tables : 0, Number of References : 45


 goto top of outline Publication Details

Intervirology (International Journal of Basic and Medical Virology)

Vol. 48, No. 4, Year 2005 (Cover Date: July-August 2005)

Journal Editor: Liebert, U.G. (Leipzig)
ISSN: 0300–5526 (print), 1423–0100 (Online)

For additional information: http://www.karger.com/int


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.